Information Provided By: 
Fly News Breaks for May 17, 2019
UTHR
May 17, 2019 | 06:37 EDT
As previously reported, UBS analyst Carter Gould upgraded United Therapeutics to Neutral but lowered his price target to $94 from $115. The analyst says that after a 26% stock price decline since late March, when Sandoz launched generic Remodulin, the risk reward on the stock has become more balanced. Gould adds that the launch was pivotal in his Sell thesis, but now sees the price already reflecting the related erosion of revenue and earnings.
News For UTHR From the Last 2 Days
There are no results for your query UTHR
